Ventrus Biosciences Inc. (Nasdaq: VTUS) reported positive results from two clinical dermal safety studies and one pharmacokinetic study of its anal fissure treatment VEN 307 sending the stock price soaring 80 cents to $3.38.
Positive Trial Results For Ventrus Biosciences
September 11, 2013 at 14:16 PM EDT
